Therapeutic challenges in peripheral T-cell lymphoma.

Area of Science:

• Hematology
• Oncology
• Cancer Biology

Background:

• Peripheral T-cell lymphoma (PTCL) is a rare, heterogeneous hematological malignancy with limited understanding compared to B-cell tumors.
• Many patients are diagnosed at advanced stages, and drug resistance leads to poor outcomes in relapsed or refractory PTCL (r/r PTCL).

Purpose of the Study:

• To review mechanisms of treatment resistance in PTCL.
• To discuss current therapeutic strategies and their limitations.
• To summarize ongoing clinical trials for r/r PTCL.

Main Methods:

• Literature review of PTCL mechanisms of resistance.
• Analysis of existing and emerging drug therapies.
• Compilation of data from ongoing clinical trials.

Main Results:

• PTCL treatment resistance is influenced by tumor heterogeneity, the tumor microenvironment, and aberrant signaling pathways.
• Existing drugs face challenges due to various resistance mechanisms.
• Several clinical trials are underway to improve r/r PTCL treatment outcomes.

Conclusions:

• Understanding PTCL resistance mechanisms is crucial for developing effective therapies.
• Targeting tumor heterogeneity, microenvironment, and signaling pathways offers potential therapeutic avenues.
• Ongoing clinical trials are vital for advancing treatment decisions and improving patient outcomes in r/r PTCL.